fig4
Figure 4. FASN inhibition attenuates TNNI3 p.R186Q-induced aberrant fatty acid metabolism and cardiac hypertrophy. Tnni3R186Q/R186Q mice at 10 months of age were administered saline or C75 (15 mg/kg/day) daily for 8 weeks. (A) Experiment timeline for